Cargando…

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

Detalles Bibliográficos
Autores principales:	Walter, Roland B., Othus, Megan, Paietta, Elisabeth M., Racevskis, Janis, Fernandez, Hugo F., Lee, Ju-Whei, Sun, Zhuoxin, Tallman, Martin S., Patel, Jay, Gönen, Mithat, Abdel-Wahab, Omar, Levine, Ross L., Estey, Elihu H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573365/ https://www.ncbi.nlm.nih.gov/pubmed/25772026 http://dx.doi.org/10.1038/leu.2015.76

Ejemplares similares

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms
por: Shih, Lauren, et al.
Publicado: (2023)

Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms
por: Paras, Gabrielle, et al.
Publicado: (2022)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
por: Zhou, Yi, et al.
Publicado: (2016)

Recent advances in the treatment of acute myeloid leukemia
por: Abdel-Wahab, Omar, et al.
Publicado: (2010)

Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition
por: Chen, Lili, et al.
Publicado: (2015)

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
por: Hochman, Michael J., et al.
Publicado: (2023)

Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
por: Godwin, Colin D., et al.
Publicado: (2022)

New drug approvals in acute myeloid leukemia: what’s the best end point?
por: Estey, E, et al.
Publicado: (2015)

Adhesion molecules in acute myeloid leukemia()
por: Paietta, Elisabeth
Publicado: (1996)

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study
por: Halpern, Anna B., et al.
Publicado: (2017)

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML)
por: Acharya, Utkarsh H., et al.
Publicado: (2018)

Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility
por: Percival, Mary-Elizabeth M., et al.
Publicado: (2020)

Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies
por: Othus, Megan, et al.
Publicado: (2018)

Prediction of CR following a second course of ‘7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course
por: Othus, M, et al.
Publicado: (2016)

Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy
por: Estey, Elihu
Publicado: (2013)

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
por: Cortes, Jorge E., et al.
Publicado: (2020)

Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2022)

Cell Signaling-Based Classifier Predicts Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia
por: Cesano, Alessandra, et al.
Publicado: (2015)

Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML
por: Sorror, Mohamed L., et al.
Publicado: (2020)

ETV6 mutations in early immature human T cell leukemias
por: Van Vlierberghe, Pieter, et al.
Publicado: (2011)

Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms
por: Halpern, Anna B., et al.
Publicado: (2018)

Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
por: Rapaport, Franck, et al.
Publicado: (2022)

Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
por: Rapaport, Franck, et al.
Publicado: (2023)

A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia
por: Lee, Su-In, et al.
Publicado: (2018)

Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL
por: Tzoneva, Gannie, et al.
Publicado: (2013)

Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells
por: Vu, Ly P., et al.
Publicado: (2017)

Genetic Inactivation of the PRC2 Complex in T-Cell Acute Lymphoblastic Leukemia
por: Ntziachristos, Panagiotis, et al.
Publicado: (2012)

Base-Pair Resolution DNA Methylation Sequencing Reveals Profoundly Divergent Epigenetic Landscapes in Acute Myeloid Leukemia
por: Akalin, Altuna, et al.
Publicado: (2012)

Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia
por: Orvain, Corentin, et al.
Publicado: (2023)

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
por: Estey, Elihu, et al.
Publicado: (2022)

A novel tumor suppressor function for the Notch pathway in myeloid leukemia
por: Klinakis, Apostolos, et al.
Publicado: (2011)

S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910
por: Litzow, Mark, et al.
Publicado: (2023)

The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy
por: Buckley, S A, et al.
Publicado: (2015)

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
por: McCarter, Joseph G. W., et al.
Publicado: (2023)

Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality
por: Sorror, Mohamed L., et al.
Publicado: (2017)

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center
por: Walter, Roland B., et al.
Publicado: (2014)

CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials
por: Ganzel, Chezi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_etps83kl75dva9tf9u1uvmo6b1